No insider purchase over the last 90 days. The latest, by 빈준길, was filed 01 Jun 2026.
NEUROPHET, Inc.: what insiders have been doing
NEUROPHET, Inc. is a Health Care company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 1 November 2026, brought 8 filings signed by 5 insiders.
The record shows 5 purchases on the open market worth €165k, made by 4 insiders, against 1 sale by 1 insider. The totals do not cover 3 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 major shareholder and 1 senior executive. At €139k, the purchase published on 30 April 2026 by 김창일 is the largest of the period (0.23% of market cap).
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 8 filings here. Since 2025, the database holds 6 purchases and 3 sales by insiders of the company.
Within a 30-day window, 3 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 162 days ago, on 1 June 2026. Filings reach the DART (FSS) feed a median of 3 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -57.6%Entry ₩13,240 · Close 30 Oct 2026 ₩5,610
- -57.6%Entry ₩13,240 · Close 30 Oct 2026 ₩5,610
- -71.9%Entry ₩19,930 · Close 30 Oct 2026 ₩5,610
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 3,000 sharesKRXDART:20260601000931Canonical exit: 27 Aug 2026 (T+90)
- 2,000 shares@ ₩14,878.330.028% mcap100.0% of flowShareKRXDART:20260601000964Canonical exit: 27 Aug 2026 (T+90)
- 1,000 shares@ ₩14,970.000.014% mcap100.0% of flowShareKRXDART:20260601000947Canonical exit: 27 Aug 2026 (T+90)
- 21,300 shares@ ₩11,313.000.23% mcap100.0% of flowShareKRXDART:20260430001451Canonical exit: 29 Jul 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 118,719 sharesKRXDART:20260303002358
- 582,764 sharesKRXDART:20260129000613Canonical exit: 22 Apr 2026 (T+90)
- 201,624 sharesKRXDART:20250904000455
- 87,715 sharesKRXDART:20250904000365
- 574,979 sharesKRXDART:20250801000939Canonical exit: 23 Oct 2025 (T+90)
11 of 11 declarations
About NEUROPHET, Inc.
Neurofit is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for patient well-being and health.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
